BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 20606044)

  • 21. Sonoporation-enhanced chemotherapy significantly reduces primary tumour burden in an orthotopic pancreatic cancer xenograft.
    Kotopoulis S; Delalande A; Popa M; Mamaeva V; Dimcevski G; Gilja OH; Postema M; Gjertsen BT; McCormack E
    Mol Imaging Biol; 2014 Feb; 16(1):53-62. PubMed ID: 23877869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic synergism of gemcitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft.
    Pratesi G; Petrangolini G; Tortoreto M; Addis A; Belluco S; Rossini A; Selleri S; Rumio C; Menard S; Balsari A
    Cancer Res; 2005 Jul; 65(14):6388-93. PubMed ID: 16024642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.
    Yabuuchi S; Pai SG; Campbell NR; de Wilde RF; De Oliveira E; Korangath P; Streppel MM; Rasheed ZA; Hidalgo M; Maitra A; Rajeshkumar NV
    Cancer Lett; 2013 Jul; 335(1):41-51. PubMed ID: 23402814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers.
    Feldmann G; Dhara S; Fendrich V; Bedja D; Beaty R; Mullendore M; Karikari C; Alvarez H; Iacobuzio-Donahue C; Jimeno A; Gabrielson KL; Matsui W; Maitra A
    Cancer Res; 2007 Mar; 67(5):2187-96. PubMed ID: 17332349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets.
    Kunnumakkara AB; Sung B; Ravindran J; Diagaradjane P; Deorukhkar A; Dey S; Koca C; Tong Z; Gelovani JG; Guha S; Krishnan S; Aggarwal BB
    Int J Cancer; 2012 Aug; 131(3):E292-303. PubMed ID: 21935918
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of Metastasis by Low-dose Gemcitabine in a Pancreatic Cancer Orthotopic Mouse Model: An Opposite Effect of Chemotherapy.
    Sugisawa N; Miyake K; Higuchi T; Oshiro H; Zhang Z; Park JH; Kawaguchi K; Chawla SP; Bouvet M; Singh SR; Unno M; Hoffman RM
    Anticancer Res; 2019 Oct; 39(10):5339-5344. PubMed ID: 31570427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced antitumor efficacy by the combination of emodin and gemcitabine against human pancreatic cancer cells via downregulation of the expression of XIAP in vitro and in vivo.
    Wang ZH; Chen H; Guo HC; Tong HF; Liu JX; Wei WT; Tan W; Ni ZL; Liu HB; Lin SZ
    Int J Oncol; 2011 Nov; 39(5):1123-31. PubMed ID: 21743963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The differential effects of metronomic gemcitabine and antiangiogenic treatment in patient-derived xenografts of pancreatic cancer: treatment effects on metabolism, vascular function, cell proliferation, and tumor growth.
    Yapp DT; Wong MQ; Kyle AH; Valdez SM; Tso J; Yung A; Kozlowski P; Owen DA; Buczkowski AK; Chung SW; Scudamore CH; Minchinton AI; Ng SS
    Angiogenesis; 2016 Apr; 19(2):229-44. PubMed ID: 26961182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metastatic pancreatic adenocarcinoma and renal cell carcinoma treated with gemcitabine and sunitinib malate. A case report.
    Bharthuar A; Pearce L; Litwin A; LeVea C; Kuvshinoff B; Iyer R
    JOP; 2009 Sep; 10(5):523-7. PubMed ID: 19734629
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer.
    Awasthi N; Kirane A; Schwarz MA; Toombs JE; Brekken RA; Schwarz RE
    BMC Cancer; 2011 Jan; 11():15. PubMed ID: 21226944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemotherapy counteracts metastatic dissemination induced by antiangiogenic treatment in mice.
    Rovida A; Castiglioni V; Decio A; Scarlato V; Scanziani E; Giavazzi R; Cesca M
    Mol Cancer Ther; 2013 Oct; 12(10):2237-47. PubMed ID: 23918831
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Yang H; Tong Z; Shen L; Sun YU; Hoffman RM; Huang J
    Anticancer Res; 2020 Sep; 40(9):4969-4978. PubMed ID: 32878785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer.
    Laheru D; Shah P; Rajeshkumar NV; McAllister F; Taylor G; Goldsweig H; Le DT; Donehower R; Jimeno A; Linden S; Zhao M; Song D; Rudek MA; Hidalgo M
    Invest New Drugs; 2012 Dec; 30(6):2391-9. PubMed ID: 22547163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.
    Bellmunt J; Suarez C; Gallardo E; Rodon J; Pons F; Bonfill T; Beltran M; Moya I; Galtes S; Albanell J; Carles J
    Oncologist; 2014 Sep; 19(9):917-8. PubMed ID: 25142843
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Z-360, a novel orally active CCK-2/gastrin receptor antagonist on tumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action determinations in vitro.
    Kawasaki D; Emori Y; Eta R; Iino Y; Hamano H; Yoshinaga K; Tanaka T; Takei M; Watson SA
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):883-92. PubMed ID: 17901954
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine.
    Jung DB; Yun M; Kim EO; Kim J; Kim B; Jung JH; Wang E; Mukhopadhyay D; Hammond E; Dredge K; Shridhar V; Kim SH
    Oncotarget; 2015 Mar; 6(7):4992-5004. PubMed ID: 25669977
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer.
    Awasthi N; Zhang C; Schwarz AM; Hinz S; Wang C; Williams NS; Schwarz MA; Schwarz RE
    Carcinogenesis; 2013 Oct; 34(10):2361-9. PubMed ID: 23803690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer.
    Bisht S; Mizuma M; Feldmann G; Ottenhof NA; Hong SM; Pramanik D; Chenna V; Karikari C; Sharma R; Goggins MG; Rudek MA; Ravi R; Maitra A; Maitra A
    Mol Cancer Ther; 2010 Aug; 9(8):2255-64. PubMed ID: 20647339
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine.
    Kimura K; Sawada T; Komatsu M; Inoue M; Muguruma K; Nishihara T; Yamashita Y; Yamada N; Ohira M; Hirakawa K
    Clin Cancer Res; 2006 Aug; 12(16):4925-32. PubMed ID: 16914581
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel red fluorescent protein orthotopic pancreatic cancer model for the preclinical evaluation of chemotherapeutics.
    Katz MH; Takimoto S; Spivack D; Moossa AR; Hoffman RM; Bouvet M
    J Surg Res; 2003 Jul; 113(1):151-60. PubMed ID: 12943825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.